Mestrualia wins CE mark for Sobek diagnostic device

Mestrualia, a Northern Italian femtech startup, has secured CE marking for Sobek, opening the door to European market access as the company prepares clinical pilots. The startup wants to test whether its blood-and-saliva biomarker approach can support earlier chronic disease assessment and women’s health prevention.

Why it matters: - Mestrualia’s CE mark gives the startup a regulatory path to sell Sobek in Europe. - The next step is clinical validation, which will determine whether the device can add useful evidence for earlier assessment of chronic disease in women’s health. - Endometriosis is one of the first conditions the company wants to study, but the longer-term goal is broader chronic disease prevention and monitoring.

What happened: - Mestrualia, a Northern Italian femtech startup founded by Franziska Roessler, secured CE marking for its Sobek diagnostic device. - The device combines blood and saliva biomarkers in a non-invasive diagnostic platform. - The CE mark allows Mestrualia to place Sobek on the European market under applicable EU medical device requirements. - The company is now preparing pilot programs for its SBK Test with clinical associations, hospitals, clinics, and diagnostic laboratories.

The details: - Sobek is designed to explore whether biological changes linked to chronic disease can be identified earlier. - Mestrualia is seeking the first real-world clinical evidence on test performance and potential use in existing healthcare pathways. - The company is in discussions with diagnostic laboratories about integrating blood and saliva sample processing into current workflows. - Mestrualia is also engaging clinical and patient organizations, especially those focused on endometriosis and chronic disease awareness. - The company’s quality management framework is based on ISO 13485. - Its risk management processes follow ISO 14971. - The technology remains under clinical evaluation. - Mestrualia is not claiming Sobek can prevent chronic disease or replace established diagnostic methods.

Between the lines: - The CE mark is an important regulatory milestone, but it does not prove clinical performance. - The company’s strategy depends on showing that biomarker-based diagnostics can provide objective information that supports earlier assessment and monitoring. - Backing from Invitalia, the Italian National Agency for Development, and regional innovation funds in Northern Italy suggests public support as the company moves from development to validation and commercial preparation. - If the pilots are successful, Sobek could fit into a broader model of prevention-oriented women’s healthcare rather than a single-disease product.

What’s next: - Mestrualia plans to run clinical pilots to measure how SBK Test results correlate with clinical findings. - The company will use those studies to test whether Sobek can support earlier assessment and monitoring in real-world settings. - Further work will focus on laboratory integration and scalability. - Clinical evidence will determine whether Sobek becomes a useful tool in women’s health pathways.

The bottom line: - Mestrualia has cleared a key regulatory hurdle, but the real test is whether Sobek can prove clinical value in practice.

More information: Mestrualia